Rahman, A., Isenberg, D.A., Systemic lupus erythematosus (2008) N Engl J Med, 358, pp. 929-939
Austin III, H.A., Klippel, J.H., Balow, J.E., Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs (1986) New England Journal of Medicine, 314 (10), pp. 614-619
Boumpas, D.T., Austin III, H.A., Vaughn, E.M., Klippel, J.H., Steinberg, A.D., Yarboro, C.H., Balow, J.E., Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis (1992) Lancet, 340, pp. 741-745
Appel, G.B., Contreras, G., Dooley, M.A., Ginzler, E.M., Isenberg, D., Jayne, D., Li, L.S., Wofsy, D., Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis (2009) J Am Soc Nephrol, 20, pp. 1103-1112
Loffler, M., Grein, K., Knecht, W., Klein, A., Bergjohann, U., Dihydroorotate dehydrogenase: Profile of a novel target for antiproliferative and immunosuppressive drugs (1998) Advances in Experimental Medicine and Biology, 431, pp. 507-513
Herrmann, M.L., Schleyerbach, R., Kirschbaum, B.J., Leflunomide: An immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases (2000) Immunopharmacology, 47, pp. 273-289
Liu, S., Neidhardt, E.A., Grossman, T.H., Ocain, T., Clardy, J., Structures of human dihydroorotate dehydrogenase in complex with antiproliferative agents (2000) Structure, 8, pp. 25-33
Smolen, J.S., Kalden, J.R., Scott, D.L., Rozman, B., Kvien, T.K., Larsen, A., Loew-Friedrich, I., Rosenburg, R., Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: A double-blind, randomised, multicentre trial (1999) Lancet, 353, pp. 259-266. , European Leflunomide Study Group
Kaltwasser, J.P., Nash, P., Gladman, D., Rosen, C.F., Behrens, F., Jones, P., Wollenhaupt, J., Mease, P., Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: A multinational, double-blind, randomized, placebo-controlled clinical trial (2004) Arthritis Rheum, 50, pp. 1939-1950
Popovic, S., Bartlett, R.R., Disease modifying activity of HWA 486 on the development of SLE in MRL/1-mice (1986) Agents Actions, 19, pp. 313-314
Leban, J., Kralik, M., Mies, J., Gassen, M., Tentschert, K., Baumgartner, R., SAR, species specificity, and cellular activity of cyclopentene dicarboxylic acid amides as DHODH inhibitors (2005) Bioorg Med Chem Lett, 15, pp. 4854-4857
Fitzpatrick, L.R., Deml, L., Hofmann, C., Small, J.S., Groeppel, M., Hamm, S., Lemstra, S., Ammendola, A., 4SC-101, a novel immunosuppressive drug, inhibits IL-17 and attenuates Colitis in two murine models of inflammatory bowel disease (2010) Inflamm Bowel Dis, , doi: 10.1002/ibd.21264
Kulkarni, O., Eulberg, D., Selve, N., Zollner, S., Allam, R., Pawar, R.D., Pfeiffer, S., Anders, H.J., Anti-Ccl2 Spiegelmer permits 75% dose reduction of cyclophosphamide to control diffuse proliferative lupus nephritis and pneumonitis in MRL-Fas(lpr) mice (2009) J Pharmacol Exp Ther, 328, pp. 371-377
Perez De Lema, G., Maier, H., Nieto, E., Vielhauer, V., Luckow, B., Mampaso, F., Schlondorff, D., Chemokine expression precedes inflammatory cell infiltration and chemokine receptor and cytokine expression during the initiation of murine lupus nephritis (2001) Journal of the American Society of Nephrology, 12 (7), pp. 1369-1382
Kulkarni, O., Pawar, R.D., Purschke, W., Eulberg, D., Selve, N., Buchner, K., Ninichuk, V., Anders, H.J., Spiegelmer inhibition of CCL2/MCP-1 ameliorates lupus nephritis in MRL-(Fas)lpr mice (2007) J Am Soc Nephrol, 18, pp. 2350-2358
Patole, P.S., Schubert, S., Hildinger, K., Khandoga, S., Khandoga, A., Segerer, S., Henger, A., Anders, H.J., Toll-like receptor-4: Renal cells and bone marrow cells signal for neutrophil recruitment during pyelonephritis (2005) Kidney Int, 68, pp. 2582-2587
Chan, O.T., Paliwal, V., McNiff, J.M., Park, S.H., Bendelac, A., Shlomchik, M.J., Deficiency in beta(2)-microglobulin, but not CD1, accelerates spontaneous lupus skin disease while inhibiting nephritis in MRL-Fas(lpr) nice: An example of disease regulation at the organ level (2001) J Immunol, 167, pp. 2985-2990
Austin III, H.A., Muenz, L.R., Joyce, K.M., Antonovych, T.T., Balow, J.E., Diffuse proliferative lupus nephritis: Identification of specific pathologic features affecting renal outcome (1984) Kidney Int, 25, pp. 689-695
Patole, P.S., Pawar, R.D., Lech, M., Zecher, D., Schmidt, H., Segerer, S., Ellwart, A., Anders, H.J., Expression and regulation of Toll-like receptors in lupus-like immune complex glomerulonephritis of MRL-Fas(lpr) mice (2006) Nephrol Dial Transplant, 21, pp. 3062-3073
Qi, Z., Whitt, I., Mehta, A., Jin, J., Zhao, M., Harris, R.C., Fogo, A.B., Breyer, M.D., Serial determination of glomerular filtration rate in conscious mice using FITC-inulin clearance (2004) American Journal of Physiology - Renal Physiology, 286 (3), pp. F590-F596
Tsou, C.L., Peters, W., Si, Y., Slaymaker, S., Aslanian, A.M., Weisberg, S.P., Mack, M., Charo, I.F., Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and recruitment to inflammatory sites (2007) J Clin Invest, 117, pp. 902-909
Cohen, P.L., Eisenberg, R.A., Lpr and gld: Single gene models of systemic autoimmunity and lymphoproliferative disease (1991) Annu Rev Immunol, 9, pp. 243-269
Goodnow, C.C., Multistep pathogenesis of autoimmune disease (2007) Cell, 130, pp. 25-35
Tam, L.S., Li, E.K., Wong, C.K., Lam, C.W., Szeto, C.C., Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus (2004) Lupus, 13, pp. 601-604
Tam, L.S., Li, E.K., Wong, C.K., Lam, C.W., Li, W.C., Szeto, C.C., Safety and efficacy of leflunomide in the treatment of lupus nephritis refractory or intolerant to traditional immunosuppressive therapy: An open label trial (2006) Ann Rheum Dis, 65, pp. 417-418
Wang, H.Y., Cui, T.G., Hou, F.F., Ni, Z.H., Chen, X.M., Lu, F.M., Xu, F.F., Zou, W.Z., Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: A prospective multi-centre observational study (2008) Lupus, 17, pp. 638-644
Marzano, A.V., Ramoni, S., Del Papa, N., Barbareschi, M., Alessi, E., Leflunomide-induced subacute cutaneous lupus erythematosus with erythema multiforme-like lesions (2008) Lupus, 17, pp. 329-331
Suess, A., Sticherling, M., Leflunomide in subacute cutaneous lupus erythematosus: Two sides of a coin (2008) Int J Dermatol, 47, pp. 83-86
Chan, S.K., Hazleman, B.L., Burrows, N.P., Subacute cutaneous lupus erythematosus precipitated by leflunomide (2005) Clin Exp Dermatol, 30, pp. 724-725
